Mezzion Pharma Statistics
Total Valuation
Mezzion Pharma has a market cap or net worth of KRW 2.82 trillion. The enterprise value is 2.81 trillion.
| Market Cap | 2.82T |
| Enterprise Value | 2.81T |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mezzion Pharma has 30.39 million shares outstanding. The number of shares has increased by 0.95% in one year.
| Current Share Class | 30.39M |
| Shares Outstanding | 30.39M |
| Shares Change (YoY) | +0.95% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | 9.22% |
| Owned by Institutions (%) | 4.83% |
| Float | 22.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 356.58 |
| PB Ratio | 164.03 |
| P/TBV Ratio | 181.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -80.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -167.81 |
Financial Position
The company has a current ratio of 0.57, with a Debt / Equity ratio of 0.69.
| Current Ratio | 0.57 |
| Quick Ratio | 0.34 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.71 |
| Interest Coverage | -10.71 |
Financial Efficiency
Return on equity (ROE) is -110.43% and return on invested capital (ROIC) is -144.73%.
| Return on Equity (ROE) | -110.43% |
| Return on Assets (ROA) | -12.24% |
| Return on Invested Capital (ROIC) | -144.73% |
| Return on Capital Employed (ROCE) | -91.26% |
| Weighted Average Cost of Capital (WACC) | 12.47% |
| Revenue Per Employee | 439.42M |
| Profits Per Employee | -1.94B |
| Employee Count | 18 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -3.91B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +139.48% in the last 52 weeks. The beta is 1.50, so Mezzion Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +139.48% |
| 50-Day Moving Average | 105,074.00 |
| 200-Day Moving Average | 79,281.75 |
| Relative Strength Index (RSI) | 48.71 |
| Average Volume (20 Days) | 146,696 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mezzion Pharma had revenue of KRW 7.91 billion and -34.93 billion in losses. Loss per share was -1,160.00.
| Revenue | 7.91B |
| Gross Profit | 1.38B |
| Operating Income | -16.84B |
| Pretax Income | -38.84B |
| Net Income | -34.93B |
| EBITDA | -15.85B |
| EBIT | -16.84B |
| Loss Per Share | -1,160.00 |
Balance Sheet
The company has 25.57 billion in cash and 11.87 billion in debt, giving a net cash position of 13.70 billion or 450.80 per share.
| Cash & Cash Equivalents | 25.57B |
| Total Debt | 11.87B |
| Net Cash | 13.70B |
| Net Cash Per Share | 450.80 |
| Equity (Book Value) | 17.19B |
| Book Value Per Share | 567.14 |
| Working Capital | -33.99B |
Cash Flow
In the last 12 months, operating cash flow was -16.59 billion and capital expenditures -137.39 million, giving a free cash flow of -16.73 billion.
| Operating Cash Flow | -16.59B |
| Capital Expenditures | -137.39M |
| Depreciation & Amortization | 988.12M |
| Net Borrowing | 22.37B |
| Free Cash Flow | -16.73B |
| FCF Per Share | -550.32 |
Margins
| Gross Margin | 17.46% |
| Operating Margin | -212.91% |
| Pretax Margin | -491.02% |
| Profit Margin | n/a |
| EBITDA Margin | -200.42% |
| EBIT Margin | -212.91% |
| FCF Margin | n/a |
Dividends & Yields
Mezzion Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.95% |
| Shareholder Yield | -0.95% |
| Earnings Yield | -1.24% |
| FCF Yield | -0.59% |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Apr 5, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Mezzion Pharma has an Altman Z-Score of 6.86 and a Piotroski F-Score of 1.
| Altman Z-Score | 6.86 |
| Piotroski F-Score | 1 |